[Is the current level of investigation for vestibular schwannoma reasonable?] / Utredningsnivån av vestibulära schwannom måste bli rimlig - Nationella riktlinjer behövs.

The main aim of this study was to evaluate if the level of investigation with MRT or BRA (Brainstem Response Audiometry) is adequate in relation to the number of vestibular schwannomas (VS) found in a county like  Dalarna (277 000 inhabitants) in Sweden. The reason to investigate was asymmetrical sensorineural hearing loss (ASHL) defined as a one-sided hearing loss exceeding 10 dB compared to the contralateral side. Between 2007-2014 a total of 55 patients (incidence 2.5/100 000) were diagnosed with a VS in the county. The local ENT department found two thirds of these patients. In the year of 2010, MRT was advocated by SBU (Swedish Agency for Health Technology Assessment and Assessment of Social Services) as the primary step of investigation. During 2011-2014, 981 patients underwent MRT and 482 patients BRA, because of ASHL. Seventeen VS were found, meaning that 58 MRT and 29 BRA were conducted to find one VS. According to earlier studies, only one third of VS show growth tendency. Taking this into consideration, 174 (58 × 3) investigations with MRT will only diagnose approximately 1 patient with a growing VS. We therefore question today's level of investigation and ask for new uniform recommendations on how to investigate for VS in cases of ASHL.

Immunohistochemical analysis of EGFR and hyaluronan in tongue cancer and the development of regional recurrence in patients initially diagnosed N0.

OBJECTIVE: To investigate whether the extent of expression of hyaluronan (HA) and epidermal growth factor receptor (EGFR) in squamous cell carcinoma of the mobile tongue can predict the risk of cervical metastasis and survival. STUDY DESIGN: Retrospective histopathologic study. METHODS: Surgical specimens from 64 patients who had undergone surgery for squamous cell carcinoma of the mobile tongue were assessed using immunohistochemistry to investigate the expression of HA and EGFR in the primary tumours, and the data were then correlated to cervical metastasis and survival. RESULTS: There was a significant correlation between the intensity of HA staining and patient survival (p .024), and a weak correlation between the staining proportion of EGFR and the risk for regional recurrence (AUC 66). CONCLUSIONS: This study indicates that immunoscoring using HA could be used to provide prognostic tools for tongue cancer, and that it might be of interest to study the prognostic properties of EGFR further concerning the risk for regional recurrence after the primary treatment.

Effect of radiotherapy on expression of hyaluronan and EGFR and presence of mast cells in squamous cell carcinoma of the head and neck.

Head and neck squamous cell carcinoma is a common form of cancer, and despite improvements in treatment during the last decades, survival rates have not significantly increased. There is therefore a need to better understand how these tumours and the adjacent tissues react to radiotherapy, the most common type of treatment for this group of tumours. In order to improve this understanding, the expression of hyaluronan (HA) and epidermal growth factor receptor (EGFR) and the presence of mast cells were mapped before and after radiotherapy using immunohistochemistry. The results showed HA and EGFR to have similar expression patterns in tumour tissue and histologically normal squamous epithelium prior to radiotherapy. Following radiotherapy, EGFR increased in histologically normal epithelium. An increased number of mast cells were also observed as a result of radiotherapy. No expression of EGFR was observed in the connective tissue either prior to or following radiotherapy.

Cross-linked hyaluronan versus collagen for injection treatment of glottal insufficiency: 2-year follow-up.

OBJECTIVES: To evaluate the long-term (24 months) clinical performance (vocal fold function) and safety of hylan B gel as compared with bovine cross-linked collagen in the treatment of patients with glottal insufficiency. MATERIAL AND METHODS: In a prospective trial, 70 patients with glottal insufficiency due to unilateral vocal fold paresis (n =35) or atrophy (n =35) were randomized to received either hylan B gel (n =47) or collagen (n =23) injections into 1 vocal fold. Forty-two of the patients were examined 24 months after treatment. Evaluations were made based on patients' subjective ratings, digitized videostroboscopic measurements, maximum phonation time and phonation quotient. RESULTS: The patients' self-ratings were significantly improved in both the hylan B gel and collagen groups. Videostroboscopic measurements of glottal closure were significantly improved for both groups. The hylan B gel group showed a trend towards less resorption at the injected vocal fold edge in comparison with the collagen group (p =0.05). No serious adverse events were observed. Twenty-eight patients dropped out of the study after 12 months: 18 had been re-injected or operated on with medialization laryngoplasty due to insufficient voice and 10 had either died of causes unrelated to the study or refused to attend follow-up. CONCLUSIONS: No long-term side-effects were found for either the hylan B gel or collagen groups after injection treatment. Both treatments resulted in significantly improved voice as rated by the patients and significantly improved glottal closure. Some resorption was noted for both substances, and approximately 25%, of the patients chose re-treatment 2 years after the initial treatment.

Cross-linked hyaluronan used as augmentation substance for treatment of glottal insufficiency: safety aspects and vocal fold function.

OBJECTIVE: To examine safety aspects and vocal fold function after vocal fold augmentation with a cross-linked hyaluronan derivative (hylan B gel) as compared with bovine collagen. STUDY DESIGN; A prospective, randomized trial. METHODS: Eighty-three patients with glottal insufficiency were treated with injection augmentation with hylan B gel and bovine collagen and were examined at 1, 6, and 12 months after treatment. Seventy patients with unilateral vocal fold paresis (n = 35) or atrophy (n = 35) were randomly assigned to receive either hylan B gel (n = 47) or collagen (n = 23) injections into one vocal fold. Thirteen patients with glottal insufficiency caused by scar defects or paresis resulting from malignant disease were included in a nonrandomized group and were treated only with hylan B gel. Evaluations were made from patients' subjective ratings (visual analogue scales), digitized videostroboscopic measurements, phonetograms, maximum phonation time, and phonation quotients. RESULTS: Twelve months after injections, the patients' self-ratings were significantly improved for both the hylan B gel and the collagen groups. In addition, the videostroboscopic measurements showed significantly improved glottal closure for both groups. However, for the hylan B gel group, vibration amplitude and glottal area variations were preserved, and this group showed significantly less resorption at the injected vocal fold edge. Furthermore, maximum phonation time had increased significantly for the hylan B gel patients (collagen, nonsignificant). No serious adverse events were observed; three patients injected with hylan B gel had temporary inflammation at the injection site, which resolved without sequelae. CONCLUSIONS: The results showed that both hylan B gel and collagen can be safely used for injection treatment of glottal insufficiency. Both treatments resulted in significantly improved voice as rated by the patients. However, the patients treated with hylan B gel showed better vocal fold status and longer maximum phonation time at 12 months after treatment as compared with patients treated with collagen.

Cross-linked hyaluronan for augmentation of the posterior pharyngeal wall: an experimental study in rats.

Velopharyngeal insufficiency can be treated in different ways. Augmentation injections of various space-filling materials have been tried, but a substance that has the ideal properties--easy to inject, non-toxic, and not immunogenic, and having a lasting effect--has not yet been found. Hylan b gel, a double cross-linked hyaluronan solution, is a new tissue augmentor that is not immunogenic and is easy to use. The purpose of this study was to evaluate the persistence of and the tissue reaction to hylan b gel injected into the posterior pharyngeal wall of 12 rats. Six rats acted as controls. A light immediate, and no late, inflammatory reaction developed in the pharyngeal mucosa after injection. Six months after injection, the gel was still present and the substance had been invaded by and surrounded by newly-formed, loose connective tissue. These results indicate that hylan b gel may be an appropriate substance in the augmentation of mild velopharyngeal insufficiency in man. However, further studies are needed to evaluate its long-term effects.